Biomind Labs Statistics
Total Valuation
Biomind Labs has a market cap or net worth of 9.31 million. The enterprise value is 10.04 million.
| Market Cap | 9.31M |
| Enterprise Value | 10.04M |
Important Dates
The next estimated earnings date is Thursday, May 28, 2026.
| Earnings Date | May 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biomind Labs has 77.57 million shares outstanding. The number of shares has increased by 0.94% in one year.
| Current Share Class | 77.57M |
| Shares Outstanding | 77.57M |
| Shares Change (YoY) | +0.94% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 36.31% |
| Owned by Institutions (%) | n/a |
| Float | 49.41M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | -5.13 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -11.31 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.01
| Current Ratio | 0.01 |
| Quick Ratio | 0.01 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.75 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -2,859.18% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 44.76% |
| Weighted Average Cost of Capital (WACC) | 42.50% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 5 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -82.86% in the last 52 weeks. The beta is 7.50, so Biomind Labs's price volatility has been higher than the market average.
| Beta (5Y) | 7.50 |
| 52-Week Price Change | -82.86% |
| 50-Day Moving Average | 0.22 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 47.68 |
| Average Volume (20 Days) | 2,430 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.35 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -811,641 |
| Pretax Income | -887,748 |
| Net Income | -887,748 |
| EBITDA | -811,083 |
| EBIT | -811,641 |
| Earnings Per Share (EPS) | -0.01 |
Balance Sheet
The company has 14,387 in cash and 786,783 in debt, with a net cash position of -772,396 or -0.01 per share.
| Cash & Cash Equivalents | 14,387 |
| Total Debt | 786,783 |
| Net Cash | -772,396 |
| Net Cash Per Share | -0.01 |
| Equity (Book Value) | -1.81M |
| Book Value Per Share | -0.02 |
| Working Capital | -1.81M |
Cash Flow
| Operating Cash Flow | -133,957 |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 558 |
| Net Borrowing | 157,293 |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Biomind Labs does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.94% |
| Shareholder Yield | -0.94% |
| Earnings Yield | -9.54% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |